## Asier Benito-Vicente

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7972409/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Familial Hypercholesterolemia: The Most Frequent Cholesterol Metabolism Disorder Caused Disease. International Journal of Molecular Sciences, 2018, 19, 3426.	4.1	78
2	The p.Leu167del Mutation in APOE Gene Causes Autosomal Dominant Hypercholesterolemia by Down-regulation of LDL Receptor Expression in Hepatocytes. Journal of Clinical Endocrinology and Metabolism, 2016, 101, 2113-2121.	3.6	71
3	Functional Analysis of LDLR (Low-Density Lipoprotein Receptor) Variants in Patient Lymphocytes to Assess the Effect of Evinacumab in Homozygous Familial Hypercholesterolemia Patients With a Spectrum of LDLR Activity. Arteriosclerosis, Thrombosis, and Vascular Biology, 2019, 39, 2248-2260.	2.4	60
4	Site-specific O-glycosylation of members of the low-density lipoprotein receptor superfamily enhances ligand interactions. Journal of Biological Chemistry, 2018, 293, 7408-7422.	3.4	57
5	Functional Characterization and Classification of Frequent Low-Density Lipoprotein Receptor Variants. Human Mutation, 2015, 36, 129-141.	2.5	41
6	Identification and in vitro characterization of two new PCSK9 Gain of Function variants found in patients with Familial Hypercholesterolemia. Scientific Reports, 2017, 7, 15282.	3.3	37
7	Validation of LDLr Activity as a Tool to Improve Genetic Diagnosis of Familial Hypercholesterolemia: A Retrospective on Functional Characterization of LDLr Variants. International Journal of Molecular Sciences, 2018, 19, 1676.	4.1	37
8	The importance of an integrated analysis of clinical, molecular, and functional data for the genetic diagnosis of familial hypercholesterolemia. Genetics in Medicine, 2015, 17, 980-988.	2.4	35
9	Characterization of the First PCSK9 Gain of Function Homozygote. Journal of the American College of Cardiology, 2015, 66, 2152-2154.	2.8	30
10	Molecular mechanisms of lipotoxicity-induced pancreatic β-cell dysfunction. International Review of Cell and Molecular Biology, 2021, 359, 357-402.	3.2	28
11	Further evidence of novel APOB mutations as a cause of familial hypercholesterolaemia. Atherosclerosis, 2018, 277, 448-456.	0.8	23
12	Mutation type classification and pathogenicity assignment of sixteen missense variants located in the EGF-precursor homology domain of the LDLR. Scientific Reports, 2020, 10, 1727.	3.3	23
13	The Arg499His gain-of-function mutation in the C-terminal domain of PCSK9. Atherosclerosis, 2019, 289, 162-172.	0.8	21
14	Structural changes induced by acidic pH in human apolipoprotein B-100. Scientific Reports, 2016, 6, 36324.	3.3	14
15	miR-27b Modulates Insulin Signaling in Hepatocytes by Regulating Insulin Receptor Expression. International Journal of Molecular Sciences, 2020, 21, 8675.	4.1	14
16	The use of targeted exome sequencing in genetic diagnosis of young patients with severe hypercholesterolemia. Scientific Reports, 2016, 6, 36823.	3.3	13
17	Analysis of LDLR variants from homozygous FH patients carrying multiple mutations in the LDLR gene. Atherosclerosis, 2017, 263, 163-170.	0.8	13
18	Boosting Cholesterol Efflux from Foam Cells by Sequential Administration of rHDL to Deliver MicroRNA and to Remove Cholesterol in a Triple ell 2D Atherosclerosis Model. Small, 2022, 18, e2105915.	10.0	13

ASIER BENITO-VICENTE

#	Article	IF	CITATIONS
19	Cholesterol Efflux Efficiency of Reconstituted HDL Is Affected by Nanoparticle Lipid Composition. Biomedicines, 2020, 8, 373.	3.2	11
20	MLb-LDLr. JACC Basic To Translational Science, 2021, 6, 815-827.	4.1	10
21	A Systematic Approach to Assess the Activity and Classification of PCSK9 Variants. International Journal of Molecular Sciences, 2021, 22, 13602.	4.1	10
22	Novel PCSK9 (Proprotein Convertase Subtilisin Kexin Type 9) Variants in Patients With Familial Hypercholesterolemia From Cape Town. Arteriosclerosis, Thrombosis, and Vascular Biology, 2021, 41, 934-943.	2.4	5
23	(r)HDL in theranostics: how do we apply HDL's biology for precision medicine in atherosclerosis management?. Biomaterials Science, 2021, 9, 3185-3208.	5.4	5
24	MLb-LDLr: LDLaren hartzaile aldaeren eragina aurresateko ikasketa automatikoko eredua. , 0, , .		0
25	ACT toxina eta mintzeko kolesterolaren arteko elkarrekintzaren azterketa. , 0, , .		0
26	Nanopartikulen lipido konposizioak rHDLen kolesterol kanpora-fluxuaren efizientzian eragina du. , 0, ,		0
27	Familial hypercholesterolemia. , 2022, , 501-524.		0